BioIncubator Manager - 0621
A BioIncubator has recently been set up at the House of Biohealth in Esch-sur-Alzette. This dedicated space should offer a suitable entrepreneurial ecosystem composed of three main pillars: infrastructure (i.e.wet-lab equipment), environment (i.e. ecosystem of public research laboratories and companies, business networks, investors, key stakeholders) and professional business support services for the validation, launch and development of spin-off companies from public research organisations as well as of independent start-up companies in the HealthTech sector. The Luxembourg Institute of Health (LIH), the Luxembourg Centre for SystemsBiomedicine (LCSB) at the University of Luxembourg (UL) and Technoport SA will lead the design and implementation of a fully operational BioIncubator within a 3-year project.
Data Scientist/Bioinformatician - GF0621
LIHis looking for a highly motivated candidate in Data Science/Bioinformatics. The focus is to support research demands of all LIH departments mostly related to the need of integration of clinical, epidemiological, digital and sociodemographic data to extract useful information and knowledge for project aimed at precision public health, biomedical research and healthcare. Overall, the candidate should be able to demonstrate a broad knowledge in statistical, machine- and deep learning methods. You will be working as a part of a cross-functional team supporting LIH’s data integration, target identification and precision health activities
Receptionist - MG0621
The Receptionist will mainly be responsible for: 1/ Ensuring the effective functioning of the reception desk of the Luxembourg Institute of Health; 2/ Carrying out miscellaneous administrative activities and basic secretarial duties.
Postdoctoral Fellow: Gut microbiome and mucosal barrier in multiple sclerosis - MD0620
We are looking for a talented candidate to apply for a MarieSkłodowska-Curie Actions (MSCA) Individual postdoctoral fellowship 2020. The interested candidate willsubmit an MSCA fellowship jointly with the‘Ecoimmunology & Microbiome Group’ headed by Prof. Mahesh S. Desai. Theresearch project will focus on the interactions between diet, the gutmicrobiome and colonic mucus in a neurodegenerative disease multiple sclerosis(MS). The project is based on the published work (Desai et al., Cell, 2016;Martens…Desai, Nature Reviews Microbiology, 2018) on the same topic andinvolves gnotobiotic mouse models, synthetic microbial communities, MS patientcohorts and key international collaborations in Europe, USA and Japan. Thepostdoc will participate in an exciting research program in an internationalresearch team with prior success with the MSCA applications. Scientific andprofessional guidance will be provided to submit the application for apostdoctoral fellowship that, if successful, could be initiated between spring2021 to early 2022. A 'bridge funding’ option may be available to start earlierin 2020 before the outcome of the fellowship application.
Finance Controller - NB0621
The Controller is the financial Key partner for the researchers whendealing with the financial backers, from the project submission to the finalreport, to ensure full funds collection.S/hemonitors the construction of the annual budget of the Institute andsupport Management with adequatefinancial analysis to steer the operations.S/heis the key partner for translating the financial information to non-financialpartners.
[Press release] New Study Further Advances the Treatment of Chronic Pain
Building on their previous findings, scientists from the Immuno-Pharmacology and Interactomics group at the Department of Infection and Immunity of the Luxembourg Institute of Health (LIH), in collaboration with the Center for Drug Discovery at RTI International (RTI), a nonprofit research institute, have demonstrated that conolidine, a natural painkiller derived from the pinwheel flower and traditionally used in Chinese medicine, interacts with the newly identified opioid receptor ACKR3/CXCR7 that regulates opioid peptides naturally produced in the brain. The researchers also developed a synthetic analogue of conolidine, RTI-5152-12, which displays an even greater activity on the receptor. These findings, which were published on June 3rd in the prestigious international journal ‘Signal Transduction and Targeted Therapy’ (Nature publishing group), further advance the understanding of pain regulation and open alternative therapeutic avenues for the treatment of chronic pain.
LIH cancer research supported by Schëfflenger Kriibshëllef donation
On May 20th 2021, the Luxembourgish non-profit association “Schëfflenger Kriibshëllef” made a donation to the LIH Department of Oncology (DONC) to support the acquisition of new laboratory equipment for cancer research.
A year of Predi-COVID
On May 5th 2020, the first participants were being enrolled in the newly launched Predi-COVID cohort. Fast-forward to May 2021, these initial volunteers have been invited to take part in the final follow-up foreseen under the study, which will specifically seek to shed light on the features of “Long COVID” through a new dedicated questionnaire.
[Press release] Luxembourg hosts international flagship cancer epidemiology conference
From May 12th until May 14th, about 150 international scientists, clinicians, healthcare professionals and policymakers from 17 nations will gather for the 45th edition of the Group of Cancer Epidemiology and Registration in Latin Language Countries (GRELL) conference which, due to the current pandemic, will take place in a fully virtual format. Organised in Luxembourg for the first time by the National Cancer Registry of Luxembourg (Registre National du Cancer - RNC) at the Luxembourg Institute of Health (LIH), the meeting will feature several prominent speakers, providing an opportunity to discuss the latest developments in the field of cancer epidemiology with a particular focus on COVID-19 and cancer, as well as childhood and adolescent cancers. This 2021 edition of the GRELL conference is dedicated to the memory of the late Dr Michel Untereiner, oncologist and Scientific Director of the RNC between January 2013 and March 2021.